Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Liabilities (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Total Liabilities for 6 consecutive years, with $24.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 15.7% year-over-year to $24.6 million, compared with a TTM value of $24.6 million through Sep 2025, down 15.7%, and an annual FY2024 reading of $30.2 million, up 9.75% over the prior year.
  • Total Liabilities was $24.6 million for Q3 2025 at Barinthus Biotherapeutics, down from $27.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $34.4 million in Q3 2023 and bottomed at $9.9 million in Q2 2021.
  • Average Total Liabilities over 5 years is $26.2 million, with a median of $28.2 million recorded in 2021.
  • The sharpest move saw Total Liabilities plummeted 66.05% in 2021, then soared 227.08% in 2022.
  • Year by year, Total Liabilities stood at $28.2 million in 2021, then fell by 4.08% to $27.0 million in 2022, then grew by 1.88% to $27.5 million in 2023, then rose by 9.75% to $30.2 million in 2024, then decreased by 18.39% to $24.6 million in 2025.
  • Business Quant data shows Total Liabilities for BRNS at $24.6 million in Q3 2025, $27.1 million in Q2 2025, and $26.4 million in Q1 2025.